PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT

Objective: Chronic myeloid leukemia (CML) is rarely seen in children. The development of myelofibrosis in CML is not uncommon and is associated with a poor prognosis. In cases unresponsive to treatment, tyrosine kinase mutation should be checked for drug resistance, second generation tyrosine kinase...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Serap Karaman, Mustafa Bilici, Ayşegül Ünüvar, Deniz Tuğcu, Gülşah Tanyıldız, Rumeysa Tuna Deveci, Gülçin Yegen, Şifa Şahin, Zeynep Karakaş
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/a1adf842c03041b58f9bd8dd0082a76e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a1adf842c03041b58f9bd8dd0082a76e
record_format	dspace
spelling	oai:doaj.org-article:a1adf842c03041b58f9bd8dd0082a76e2021-11-10T04:38:44ZPONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT2531-137910.1016/j.htct.2021.10.1084https://doaj.org/article/a1adf842c03041b58f9bd8dd0082a76e2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921012311https://doaj.org/toc/2531-1379Objective: Chronic myeloid leukemia (CML) is rarely seen in children. The development of myelofibrosis in CML is not uncommon and is associated with a poor prognosis. In cases unresponsive to treatment, tyrosine kinase mutation should be checked for drug resistance, second generation tyrosine kinase inhibitor (TKI) drugs (dasatinib/nilotinib) should be switched to and a suitable donor for bone marrow transplantation should be sought. Third-choice TKI can be used in children who are unresponsive to treatment and do not have a suitable donor. Materials and Methods: Experience of third-choice TKI(ponatinib) in a child with CML diagnosis due to unresponsiveness to treatment. Results: A 5.5-year-old female patient with no known disease was referred to us because of hepatosplenomegaly (liver 5 cm, spleen 10 cm). There was no laboratory disorder except for anemia (hgb 8.9 g/dL) and high LDH (1104 U/L). WBC was 11.1 × 103/µL neu 6.92 × 103/ µL plt 304000/µL. Peripheral smear showed leukoerythroblastosis. Bone marrow biopsy result was evaluated as compatible with myelofibrosis and an increase in blast rate from 8% to 18% in the bone marrow. The patient was diagnosed CML accelerated phase with cytogenetic (46,XX,t(9:22)(q34;q11))and translocation (t(9:22)- p210,BCR/ABL positive) results and. Imatinib treatment was started at 400 mg/m2.The copy number of BCR-ABL p210 checked before treatment was 72% IS. However, the patient developed febrile neutropenia, and imatinib dose reduction (< 200 mg/m2) and interruption were required in the follow-up.Under imatinib treatment, BCR-ABL copy number was 16%IS at 1 month, 11%IS at 3 months, and 95%IS at 5 months. Due to the increase in the BCR-ABL copy number, nilotinib was switched to as a second-choice TKI(230 g/m2/dose, in 2 doses).No mutation could be detected in the c-ABL gene, which was examined for tyrosine kinase resistance. HLA groups were sent from the family and compatible donors were not found. Due to severe neutropenia in the follow-up, nilotinib could be continued at 50% dose. Under nilotinib treatment, the BCR-ABL copy number was 13% IS at 1 month, 10% IS at 2 months, and 31% IS at 3 months. The patient was started on ponatinib (18 mg/m2/day) as a third choice TKI. However, due to the deep neutropenia of the patient, it was possible to continue with a dose of 10 mg/m2 from the 2nd week. With this dose, the neutrophil is around 0.8-1 × 103/µL. Under ponatinib treatment, BCR-ABL copy number was 6.6% IS at 1 month, 0.8% IS at 3 months, 0.09% at 5 months, and 0.05% at 6 months. No significant side effects were observed except neutropenia. Conclusion: There is no approved treatment in pediatric CML cases where the second choice TKI fails and there is no donor for transplantation. FDA approval for ponatinib in adult patients was obtained in December 2020. Ponatinib is a natural or mutant pan-BCR-ABL mutation inhibitor. It also inhibits VEGFR, FGFR,PDGFR,EPH and SRC kinases as well as KIT,RET,TIE2 and FLT3. The use of ponatinib should be evaluated by monitoring side effects/tolerance in pediatric cases where there is no other treatment option, and there is a need for studies on this subject.Serap KaramanMustafa BiliciAyşegül ÜnüvarDeniz TuğcuGülşah TanyıldızRumeysa Tuna DeveciGülçin YegenŞifa ŞahinZeynep KarakaşElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S60-S61 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Serap Karaman Mustafa Bilici Ayşegül Ünüvar Deniz Tuğcu Gülşah Tanyıldız Rumeysa Tuna Deveci Gülçin Yegen Şifa Şahin Zeynep Karakaş PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
description	Objective: Chronic myeloid leukemia (CML) is rarely seen in children. The development of myelofibrosis in CML is not uncommon and is associated with a poor prognosis. In cases unresponsive to treatment, tyrosine kinase mutation should be checked for drug resistance, second generation tyrosine kinase inhibitor (TKI) drugs (dasatinib/nilotinib) should be switched to and a suitable donor for bone marrow transplantation should be sought. Third-choice TKI can be used in children who are unresponsive to treatment and do not have a suitable donor. Materials and Methods: Experience of third-choice TKI(ponatinib) in a child with CML diagnosis due to unresponsiveness to treatment. Results: A 5.5-year-old female patient with no known disease was referred to us because of hepatosplenomegaly (liver 5 cm, spleen 10 cm). There was no laboratory disorder except for anemia (hgb 8.9 g/dL) and high LDH (1104 U/L). WBC was 11.1 × 103/µL neu 6.92 × 103/ µL plt 304000/µL. Peripheral smear showed leukoerythroblastosis. Bone marrow biopsy result was evaluated as compatible with myelofibrosis and an increase in blast rate from 8% to 18% in the bone marrow. The patient was diagnosed CML accelerated phase with cytogenetic (46,XX,t(9:22)(q34;q11))and translocation (t(9:22)- p210,BCR/ABL positive) results and. Imatinib treatment was started at 400 mg/m2.The copy number of BCR-ABL p210 checked before treatment was 72% IS. However, the patient developed febrile neutropenia, and imatinib dose reduction (< 200 mg/m2) and interruption were required in the follow-up.Under imatinib treatment, BCR-ABL copy number was 16%IS at 1 month, 11%IS at 3 months, and 95%IS at 5 months. Due to the increase in the BCR-ABL copy number, nilotinib was switched to as a second-choice TKI(230 g/m2/dose, in 2 doses).No mutation could be detected in the c-ABL gene, which was examined for tyrosine kinase resistance. HLA groups were sent from the family and compatible donors were not found. Due to severe neutropenia in the follow-up, nilotinib could be continued at 50% dose. Under nilotinib treatment, the BCR-ABL copy number was 13% IS at 1 month, 10% IS at 2 months, and 31% IS at 3 months. The patient was started on ponatinib (18 mg/m2/day) as a third choice TKI. However, due to the deep neutropenia of the patient, it was possible to continue with a dose of 10 mg/m2 from the 2nd week. With this dose, the neutrophil is around 0.8-1 × 103/µL. Under ponatinib treatment, BCR-ABL copy number was 6.6% IS at 1 month, 0.8% IS at 3 months, 0.09% at 5 months, and 0.05% at 6 months. No significant side effects were observed except neutropenia. Conclusion: There is no approved treatment in pediatric CML cases where the second choice TKI fails and there is no donor for transplantation. FDA approval for ponatinib in adult patients was obtained in December 2020. Ponatinib is a natural or mutant pan-BCR-ABL mutation inhibitor. It also inhibits VEGFR, FGFR,PDGFR,EPH and SRC kinases as well as KIT,RET,TIE2 and FLT3. The use of ponatinib should be evaluated by monitoring side effects/tolerance in pediatric cases where there is no other treatment option, and there is a need for studies on this subject.
format	article
author	Serap Karaman Mustafa Bilici Ayşegül Ünüvar Deniz Tuğcu Gülşah Tanyıldız Rumeysa Tuna Deveci Gülçin Yegen Şifa Şahin Zeynep Karakaş
author_facet	Serap Karaman Mustafa Bilici Ayşegül Ünüvar Deniz Tuğcu Gülşah Tanyıldız Rumeysa Tuna Deveci Gülçin Yegen Şifa Şahin Zeynep Karakaş
author_sort	Serap Karaman
title	PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
title_short	PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
title_full	PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
title_fullStr	PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
title_full_unstemmed	PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
title_sort	ponatinib experience in a pediatric chronic myeloid leukemia patient
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/a1adf842c03041b58f9bd8dd0082a76e
work_keys_str_mv	AT serapkaraman ponatinibexperienceinapediatricchronicmyeloidleukemiapatient AT mustafabilici ponatinibexperienceinapediatricchronicmyeloidleukemiapatient AT aysegulunuvar ponatinibexperienceinapediatricchronicmyeloidleukemiapatient AT deniztugcu ponatinibexperienceinapediatricchronicmyeloidleukemiapatient AT gulsahtanyıldız ponatinibexperienceinapediatricchronicmyeloidleukemiapatient AT rumeysatunadeveci ponatinibexperienceinapediatricchronicmyeloidleukemiapatient AT gulcinyegen ponatinibexperienceinapediatricchronicmyeloidleukemiapatient AT sifasahin ponatinibexperienceinapediatricchronicmyeloidleukemiapatient AT zeynepkarakas ponatinibexperienceinapediatricchronicmyeloidleukemiapatient
_version_	1718440583298547712

PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT

Ejemplares similares